Stock listing
BOATS:ARDX Ardelyx, Inc. Stock
US listing (BOATS) of Ardelyx, Inc. · home listing NASDAQ:ARDX
Follow Ardelyx, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ARDX
$2.99 USD -0.13 (-4.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ARDX
- Day range
- $2.95 – $3.08 USDNov 20, 2026
- Volume
- 6.20M sharesNov 20, 2026
- Market cap
- $751.6M USDAt the close on Nov 20, 2026 · price × 251.4M shares outstanding
- 52-week range
- $2.80 – $8.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $14.80M USDMedian day 4.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ARDX · Home | $2.99 USD | -0.13 (-4.2%) | 6,200,407 | $3.01 | $3.08 | $2.95 | $3.12 | Close on Nov 20, 2026 |
| Frankfurt:41X | €2.76 EUR | -0.06 (-2.1%) | — | €2.76 | €2.76 | €2.76 | €2.82 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARDX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.99 | -0.13 | -4.2% | $3.01 | $3.08 | $2.95 | 6,200,407 | |
| $3.12 | -0.06 | -1.9% | $3.23 | $3.26 | $3.085 | 4,746,149 | |
| $3.18 | +0.11 | +3.6% | $3.08 | $3.19 | $3.05 | 4,393,736 | |
| $3.07 | -0.02 | -0.6% | $3.09 | $3.12 | $3.04 | 3,795,808 | |
| $3.09 | -0.03 | -1.0% | $3.15 | $3.15 | $3.05 | 2,380,472 | |
| $3.12 | -0.01 | -0.3% | $3.15 | $3.165 | $3.01 | 4,033,058 | |
| $3.13 | +0.12 | +4.0% | $3.04 | $3.15 | $2.95 | 3,292,457 | |
| $3.01 | +0.08 | +2.7% | $2.90 | $3.04 | $2.90 | 5,466,005 | |
| $2.93 | +0.05 | +1.7% | $2.91 | $3.02 | $2.80 | 6,448,072 | |
| $2.88 | -0.11 | -3.7% | $2.99 | $2.99 | $2.84 | 5,441,741 | |
| $2.99 | -0.30 | -9.1% | $3.27 | $3.30 | $2.96 | 7,750,986 | |
| $3.29 | +0.26 | +8.6% | $3.41 | $3.41 | $3.085 | 10,583,598 | |
| $3.03 | 0.00 | 0.0% | $3.06 | $3.10 | $3.02 | 6,118,737 | |
| $3.03 | 0.00 | 0.0% | $3.00 | $3.085 | $2.975 | 4,602,633 | |
| $3.03 | -0.07 | -2.3% | $3.09 | $3.119 | $2.96 | 3,625,598 | |
| $3.10 | 0.00 | 0.0% | $3.12 | $3.16 | $3.075 | 2,549,379 | |
| $3.10 | +0.10 | +3.3% | $2.98 | $3.11 | $2.955 | 3,939,570 | |
| $3.00 | 0.00 | 0.0% | $3.01 | $3.04 | $2.97 | 4,856,285 | |
| $3.00 | -0.08 | -2.6% | $3.08 | $3.11 | $2.99 | 4,996,880 | |
| $3.08 | -0.12 | -3.8% | $3.17 | $3.20 | $3.02 | 4,814,624 | |
| $3.20 | +0.07 | +2.2% | $3.13 | $3.22 | $3.11 | 2,723,800 | |
| $3.13 | -0.08 | -2.5% | $3.23 | $3.23 | $3.12 | 3,017,464 | |
| $3.21 | +0.12 | +3.9% | $3.10 | $3.25 | $3.10 | 3,964,190 | |
| $3.09 | 0.00 | 0.0% | $3.09 | $3.13 | $3.05 | 3,227,276 | |
| $3.09 | -0.18 | -5.5% | $3.26 | $3.265 | $3.08 | 5,775,900 | |
| $3.27 | +0.08 | +2.5% | $3.24 | $3.35 | $3.19 | 4,072,100 | |
| $3.19 | +0.07 | +2.2% | $3.10 | $3.25 | $3.06 | 5,822,300 | |
| $3.12 | -0.11 | -3.4% | $3.20 | $3.205 | $3.09 | 6,872,700 | |
| $3.23 | -0.05 | -1.5% | $3.28 | $3.28 | $3.18 | 3,537,400 | |
| $3.28 | +0.01 | +0.3% | $3.26 | $3.30 | $3.21 | 2,356,900 | |
| $3.27 | +0.01 | +0.3% | $3.23 | $3.30 | $3.18 | 6,538,200 | |
| $3.26 | -0.05 | -1.5% | $3.26 | $3.35 | $3.22 | 5,388,100 | |
| $3.31 | -0.08 | -2.4% | $3.39 | $3.408 | $3.23 | 5,815,800 | |
| $3.39 | +0.05 | +1.5% | $3.35 | $3.42 | $3.28 | 4,252,900 | |
| $3.34 | -0.04 | -1.2% | $3.38 | $3.40 | $3.29 | 4,092,100 | |
| $3.38 | -0.04 | -1.2% | $3.46 | $3.46 | $3.355 | 4,107,200 | |
| $3.42 | +0.03 | +0.9% | $3.43 | $3.46 | $3.365 | 4,411,900 | |
| $3.39 | -0.02 | -0.6% | $3.42 | $3.435 | $3.31 | 4,433,800 | |
| $3.41 | -0.01 | -0.3% | $3.40 | $3.44 | $3.375 | 3,318,100 | |
| $3.42 | -0.03 | -0.9% | $3.47 | $3.485 | $3.40 | 2,126,100 | |
| $3.45 | -0.03 | -0.9% | $3.47 | $3.49 | $3.415 | 3,231,500 | |
| $3.48 | -0.14 | -3.9% | $3.60 | $3.62 | $3.42 | 6,279,600 | |
| $3.62 | +0.12 | +3.4% | $3.54 | $3.63 | $3.47 | 3,988,100 | |
| $3.50 | +0.08 | +2.3% | $3.455 | $3.525 | $3.37 | 2,833,500 | |
| $3.42 | +0.04 | +1.2% | $3.38 | $3.445 | $3.33 | 6,434,200 | |
| $3.38 | -0.01 | -0.3% | $3.44 | $3.495 | $3.34 | 4,228,700 | |
| $3.39 | -0.01 | -0.3% | $3.40 | $3.43 | $3.34 | 5,377,800 | |
| $3.40 | -0.12 | -3.4% | $3.52 | $3.521 | $3.38 | 5,095,900 | |
| $3.52 | -0.06 | -1.7% | $3.60 | $3.60 | $3.51 | 4,364,000 | |
| $3.58 | -0.04 | -1.1% | $3.65 | $3.68 | $3.56 | 5,690,300 | |
| $3.62 | -0.18 | -4.7% | $3.77 | $3.78 | $3.61 | 4,040,500 | |
| $3.80 | +0.03 | +0.8% | $3.73 | $3.915 | $3.69 | 4,470,500 | |
| $3.77 | -0.01 | -0.3% | $3.76 | $3.80 | $3.71 | 2,958,700 | |
| $3.78 | +0.07 | +1.9% | $3.68 | $3.78 | $3.68 | 2,981,800 | |
| $3.71 | -0.09 | -2.4% | $3.80 | $3.83 | $3.685 | 3,470,500 | |
| $3.80 | +0.04 | +1.1% | $3.75 | $3.835 | $3.725 | 3,913,600 | |
| $3.76 | -0.02 | -0.5% | $3.78 | $3.815 | $3.75 | 3,645,300 | |
| $3.78 | -0.03 | -0.8% | $3.80 | $3.81 | $3.68 | 3,801,700 | |
| $3.81 | -0.01 | -0.3% | $3.81 | $3.90 | $3.75 | 5,133,400 | |
| $3.82 | -0.01 | -0.3% | $3.83 | $3.86 | $3.79 | 2,285,900 | |
| $3.83 | +0.05 | +1.3% | $3.845 | $3.89 | $3.775 | 2,914,300 | |
| $3.78 | +0.04 | +1.1% | $3.75 | $3.925 | $3.75 | 3,428,400 | |
| $3.74 | -0.15 | -3.9% | $3.88 | $3.89 | $3.725 | 5,210,900 | |
| $3.89 | -0.01 | -0.3% | $3.92 | $3.97 | $3.88 | 2,878,900 | |
| $3.90 | -0.13 | -3.2% | $4.04 | $4.067 | $3.86 | 4,565,300 |
Splits
1 split · NASDAQ:ARDX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 4-for-1 | Split |
- Ticker
- BOATS:ARDX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Latest earnings call · Nov 3, 2026
Ardelyx (NASDAQ:ARDX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 3, 2026
Q3 2026 Earnings Presentation
Earnings · 15 slides
Latest news
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Nov 10, 2026
Closed $3.01 (+2.7%) on Nov 10, 2026
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026
Closed $3.29 (+8.6%) on Nov 4, 2026
Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation
Nov 3, 2026
Closed $3.03 (0.0%) on Nov 3, 2026
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
Oct 23, 2026
Closed $3.00 (-2.6%) on Oct 26, 2026
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
Oct 20, 2026
Closed $3.21 (+3.9%) on Oct 20, 2026
Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C
Oct 12, 2026
Closed $3.23 (-1.5%) on Oct 12, 2026
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
Oct 5, 2026
Closed $3.39 (+1.5%) on Oct 5, 2026
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
Sep 30, 2026
Closed $3.42 (+0.9%) on Sep 30, 2026
Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
Aug 6, 2026
Closed $4.00 (-17.9%) on Aug 7, 2026
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $4.00 (-17.9%) on Aug 7, 2026
Ardelyx, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 29 in the last 12 months · 203 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 16 calls with a replay · 16 with a transcript · latest Nov 3, 2026
- Decks
- 20 decks · latest Nov 3, 2026
Where Ardelyx, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ARDX · Home listing | NASDAQ | United States | USD |
| gettex:41X | gettex | Germany | EUR |
| LS Exchange:A116X0 | LS Exchange | Germany | EUR |
| Tradegate:41X | Tradegate | Germany | EUR |
| BMV:ARDX | BMV | Mexico | MXN |
| Frankfurt:41X | Frankfurt | Germany | EUR |
| Lang & Schwarz:A116X0 | Lang & Schwarz | Germany | EUR |
| BIVA:ARDX | BIVA | Mexico | MXN |
| BOATS:ARDX · This page | BOATS | United States | USD |
| BX Swiss:41X | BX Swiss | Switzerland | CHF |
| Dusseldorf:41X | Dusseldorf | Germany | EUR |
| Hamburg:41X | Hamburg | Germany | EUR |
| Munich:41X | Munich | Germany | EUR |
| Stuttgart:41X | Stuttgart | Germany | EUR |
Valuation
EV/sales 1.5× against a median of 2.6×: 3rd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $718.6M USD
- P/E
- Loss
- EV/sales
- 1.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.6×
- Gross margin
- 94.3%
- Operating margin
- −7.7%
- Net margin
- −11.8%
- Debt to equity
- 1.5×
- Beta vs S&P 500
- 0.88
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ardelyx, Inc. · NASDAQ:ARDX | US$751.6M | US$718.6M | n/a | 1.5× | n/a | 4.6× | −11.8% | 1.5× | 0.88 |
| Zhejiang Ausun Pharmaceutical Co., Ltd. Class A · SSE:603229 | US$780.2M | US$640.1M | n/a | 5.6× | n/a | 2.3× | −0.6% | 0.0× | n/a |
| Jinghua Pharmaceutical Group Co., Ltd. Class A · SZSE:002349 | US$774.6M | US$606.2M | 22.2× | 2.7× | n/a | 1.8× | 15.7% | 0.0× | n/a |
| Dezhan Healthcare Co., Ltd. Class A · SZSE:000813 | US$768.0M | US$680.7M | n/a | 13.0× | n/a | 1.1× | −111.1% | 0.0× | n/a |
| Knight Therapeutics, Inc. · TSX:GUD | US$763.2M | US$683.4M | 68.5× | 1.7× | 10.5× | 1.4× | 2.8% | 0.0× | 0.33 |
| Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A · SZSE:002424 | US$757.0M | US$728.7M | n/a | 2.1× | n/a | 1.6× | −5.5% | 0.0× | n/a |
| Luye Pharma Group Ltd. · HKEX:2186 | US$751.7M | US$1.02B | 8.1× | 1.1× | 3.3× | 0.3× | 9.8% | 0.8× | n/a |
| Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B | US$738.6M | US$950.5M | 8.3× | 1.1× | 4.8× | 1.2× | 10.0% | 0.6× | n/a |
| Bliss GVS Pharma Limited · NSE:BLISSGVS | US$735.1M | US$716.7M | 42.3× | 6.2× | 28.1× | 5.3× | 15.0% | 0.0× | n/a |
| Hunan Fangsheng Pharmaceutical Co., Ltd. Class A · SSE:603998 | US$732.2M | US$694.9M | 14.9× | 2.5× | n/a | 2.7× | 17.4% | 0.0× | n/a |
| Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A · SZSE:002082 | US$729.9M | US$658.8M | n/a | 5.0× | n/a | 1.9× | −20.2% | 0.1× | n/a |
| Median of the others | US$754.3M | US$689.2M | 18.6× | 2.6× | 7.6× | 1.7× | 6.3% | 0.0× | 0.33 |
Forecasts
10 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.20 · 7 analysts
- Revenue, year to Dec 2026
- 482.2M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Mike Raab | President & Chief Executive Officer |
| Sue Hohenleitner | Chief Financial Officer |
| Felecia Ettenberg | Chief Legal Officer |
| Caitlin Lowie | Ardelyx Investor Relations and Corporate |
| Lindsey Manuel | Associate Director, Corporate Communications |
| Lisa Caperelli | SVP, Investor Relations & Corporate Communications |
| Jamie Brady | Chief Human Resources Officer |
| John Bishop | Chief Technical and Quality Officer |
| Laura Williams | Chief Patient Officer Emeritus |
| Mike Kelliher | Chief Business Officer |
| Rajani Dinavahi | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| David Mott | Chairman |
| Merdad Parsey | Director |
| Mike Raab | President & Chief Executive Officer |
| Muna Bhanji | Director |
| Onaiza Cadoret-Manier | Director |
| Richard Rodgers | Director |
| Robert Bazemore | Director |
| William A. Bertrand | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Ardelyx (NASDAQ:ARDX) Q3 2026 Earnings Call | Tue, Nov 03, 2026 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q1 2026 Earnings Call | Thu, Apr 30, 2026 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q4 2025 Earnings Call | Thu, Feb 19, 2026 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q2 2025 Earnings Call | Mon, Aug 04, 2025 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q1 2025 Earnings Call | Thu, May 01, 2025 · 4:00 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q4 2024 Earnings Call | Thu, Feb 20, 2025 · 8:00 AM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q3 2024 Earnings Call | Thu, Oct 31, 2024 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 4:30 PM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| Ardelyx (NASDAQ:ARDX) Q1 2024 Earnings Call | Thu, May 02, 2024 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q4 2023 Earnings Call | Thu, Feb 22, 2024 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q3 2023 Earnings Call | Tue, Oct 31, 2023 · 8:00 AM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q4 2022 Earnings Call | Thu, Mar 02, 2023 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q2 2022 Earnings Call | Thu, Aug 04, 2022 · 4:30 PM ET | Replay |
| Ardelyx (NASDAQ:ARDX) Q4 2021 Earnings Call | Mon, Feb 28, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · After close | +8.6% |
| Q2 2026 | Aug 6, 2026 · After close | −17.9% |
| Q1 2026 | Apr 30, 2026 · After close | +8.7% |
| Q4 2025 | Mar 11, 2026 | −7.5% |
| Q3 2025 | Oct 30, 2025 · After close | +21.0% |
| Q2 2025 | Aug 4, 2025 · After close | +16.9% |
| Q1 2025 | May 1, 2025 · After close | −24.5% |
| Q4 2024 | Feb 20, 2025 · Before open | −10.1% |
| Q3 2024 | Oct 31, 2024 · After close | +3.8% |
| Q2 2024 | Aug 1, 2024 · After close | +10.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +28.4% |
| Q4 2023 | Feb 22, 2024 · After close | −1.6% |
| Q3 2023 | Oct 31, 2023 · Before open | +9.1% |
| Q2 2023 | Aug 2, 2023 · Before open | +5.2% |
| Q1 2023 | May 3, 2023 · After close | +0.4% |
| Q4 2022 | Mar 2, 2023 · After close | +32.2% |
| Q3 2022 | Nov 3, 2022 · After close | 0.0% |
| Q2 2022 | Aug 4, 2022 · After close | +4.0% |
| Q1 2022 | May 5, 2022 · After close | −3.3% |
| Q4 2021 | Feb 28, 2022 · After close | −5.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 15 slides | Nov 3, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 18 slides | Aug 6, 2026 |
| Investor Presentation (August 2026) | Investor deck | 30 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 23 slides | Apr 30, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 19, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 22 slides | Aug 4, 2025 |
| Corporate Update (December 2019) | Corporate update | 22 slides | Dec 3, 2019 |
| J.P. Morgan Healthcare Conference 2019 | Conference | 20 slides | Jan 7, 2019 |
| Corporate Update (October 2017) | Corporate update | 26 slides | Oct 11, 2017 |
| Q2 2017 Earnings Presentation | Earnings | 22 slides | Aug 8, 2017 |
All 20 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2017) | Investor deck | 20 slides | Jun 22, 2017 |
| JPMorgan 2017 Annual Healthcare Conference | Conference | 40 slides | Jan 9, 2017 |
| Technical Presentation (May 2015) | Technical | 18 slides | May 19, 2015 |
| Investor Presentation (February 2015) | Investor deck | 45 slides | Feb 9, 2015 |
| Technical Presentation (2015) | Technical | 14 slides | 2015 |
| Technical Presentation (2015) | Technical | 19 slides | 2015 |
| Technical Presentation (November 2014) | Technical | 12 slides | Nov 14, 2014 |
| Corporate Update (October 2014) | Corporate update | 10 slides | Oct 1, 2014 |
| Investor Presentation (August 2014) | Investor deck | 37 slides | Aug 6, 2014 |
| Technical Presentation (2014) | Technical | 12 slides | 2014 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 407.3M | 333.6M | 124.5M | 52.2M | 10.1M | 7.57M | 5.28M | 2.61M | 42.0M | 24.0M |
| Cost of revenue | 39.5M | 50.6M | 17.8M | 4.12M | 1.00M | 145.0K | 600.0K | 466.0K | 8.40M | 1.29M |
| Gross profit | 364.7M | 283.1M | 106.7M | 48.0M | 9.10M | 7.43M | 4.68M | 2.14M | 33.6M | 22.7M |
| Research and development | 71.5M | 52.3M | 35.5M | 35.2M | 91.1M | 65.1M | 71.7M | 69.4M | 75.5M | 94.2M |
| Selling, general and administrative | 337.2M | 258.7M | 134.4M | 76.6M | 72.3M | 33.2M | 24.3M | 23.7M | 23.2M | 18.7M |
| Operating income | -41.0M | -27.9M | -63.3M | -63.8M | -154.3M | -90.8M | -91.3M | -90.9M | -65.1M | -112.9M |
| Depreciation and amortization | 3.06M | 2.06M | 1.29M | 1.14M | 2.81M | 2.54M | 2.50M | 2.70M | 2.60M | 1.30M |
| EBITDA | -37.9M | -25.9M | -62.0M | -62.6M | -151.5M | -88.2M | -88.8M | -88.2M | -62.5M | -111.6M |
| Interest expense | 20.1M | 13.0M | 4.95M | 3.40M | 4.50M | 5.10M | 5.73M | 3.53M | 0 | 0 |
| Income before tax | -60.6M | -38.9M | -65.5M | -67.2M | -158.2M | -94.3M | -94.6M | -91.3M | -63.2M | -112.4M |
| Income tax | 969.0K | 266.0K | 547.0K | 8.00K | 4.00K | 2.00K | 303.0K | 4.00K | 1.18M | 29.0K |
| Net income | -61.6M | -39.1M | -66.1M | -67.2M | -158.2M | -94.3M | -94.9M | -91.3M | -64.3M | -112.4M |
| Earnings per share, basic | -0.26 | -0.17 | -0.30 | -0.42 | -1.52 | -1.05 | -1.47 | -1.62 | -1.36 | -2.80 |
| Earnings per share, diluted | -0.26 | -0.17 | -0.30 | -0.42 | -1.52 | -1.05 | -1.47 | -1.62 | -1.36 | -2.80 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 68.0M | 64.9M | 21.5M | 96.1M | 72.4M | 91.0M | 181.1M | 78.8M | 75.4M | 74.6M |
| Short-term investments | 196.7M | 185.2M | 162.8M | 27.8M | 44.3M | 95.5M | 66.4M | 89.3M | 58.6M | 126.2M |
| Receivables | 71.8M | 57.7M | 22.0M | 7.73M | 502.0K | 0 | 750.0K | 5.08M | 10.8M | |
| Inventory | 123.1M | 91.2M | 49.5M | 28.3M | 0 | 1 | 1 | 0 | ||
| Current assets | 382.3M | 356.5M | 246.1M | 153.6M | 133.6M | 194.7M | 252.1M | 176.4M | 149.7M | 204.0M |
| Property, plant and equipment | 2.18M | 1.50M | 1.01M | 1.22M | 2.36M | 1.94M | 3.44M | 5.61M | 8.03M | 8.99M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 501.6M | 435.8M | 297.6M | 190.1M | 149.9M | 201.6M | 259.8M | 183.3M | 157.9M | 213.1M |
| Accounts payable | 19.2M | 16.0M | 11.1M | 10.9M | 4.28M | 5.63M | 2.19M | 1.15M | 3.93M | 5.63M |
| Current liabilities | 88.6M | 77.8M | 50.4M | 65.6M | 52.8M | 28.4M | 22.2M | 17.7M | 17.9M | 19.2M |
| Long-term debt | 202.8M | 150.9M | 49.8M | 46.6M | 48.8M | 49.2M | 0 | 0 | ||
| Total debt | 202.8M | 150.9M | 49.8M | 26.7M | 32.3M | 50.8M | 50.0M | 52.0M | ||
| Total liabilities | 334.7M | 262.5M | 130.8M | 91.7M | 67.3M | 75.5M | 73.1M | 67.5M | 18.6M | 20.0M |
| Shareholders' equity | 166.9M | 173.3M | 166.8M | 98.3M | 82.6M | 126.1M | 186.7M | 115.8M | 139.3M | 193.2M |
| Shares outstanding | 244.4M | 238.0M | 232.5M | 198.6M | 130.2M | 93.6M | 88.8M | 62.5M | 47.5M | 47.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -42.5M | -44.8M | -89.7M | -70.0M | -152.6M | -81.4M | -76.5M | -70.3M | -65.2M | -92.5M |
| Capital spending | -1.49M | -1.01M | -344.0K | -55.0K | -1.87M | -324.0K | -325.0K | -311.0K | -2.35M | -4.87M |
| Free cash flow | -44.0M | -45.8M | -90.1M | -70.1M | -154.4M | -81.8M | -76.8M | -70.6M | -67.5M | -97.4M |
| Cash from investing | -8.96M | -18.3M | -131.2M | 18.4M | 50.9M | -31.4M | 23.4M | -29.9M | 65.3M | -131.1M |
| Cash from financing | 54.5M | 106.6M | 146.3M | 75.3M | 83.0M | 22.8M | 155.5M | 103.6M | 685.0K | 191.2M |
| Dividends paid | -25.9M | -106.0K | 0 | 0 | ||||||
| Share buybacks | 8.14M | 1.17M | 71.8M | -106.0K | 22.9M | 155.1M | 54.3M | 685.0K | 191.2M | |
| Change in cash | 3.07M | 43.5M | -74.7M | 23.7M | -18.6M | -90.1M | 102.4M | 3.38M | 785.0K | -32.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 17, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 11, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 10, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2026 | Financing | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Jun 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | May 26, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | May 19, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 19, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 19, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 8-K · Current report | Dec 17, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 7, 2025 | Insider trade | SEC |
| S-3ASR · Registration statement | Nov 3, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 3, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 28, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 14, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 3, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 2, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 20, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 20, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 12, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
This page holds 200 of 1,013 filings. Open Filings
Cap table
Built by 6ix from Ardelyx, Inc.’s releases · as of Oct 27, 2026
- Common shares
- 251,372,553
- Fully diluted
- 251,372,553
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 251,372,553 | Oct 27, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 27, 2026 | 251,372,553 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Mott Other companies: Novavax, Inc. (Director · Since at least Jun 16, 2020); Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Enliven Therapeutics, Inc. (Director · Mar 11, 2020 – Jun 2, 2022 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jul 1, 2024 · Past); Epizyme Inc (Director · May 30, 2013 – Aug 12, 2022 · Past); Omthera Pharmaceuticals Inc (Director · Apr 11, 2013 – Jul 18, 2013 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past); Medimmune Inc (Vice Chair. of the Board, CEO, Director · Feb 23, 2006 – Jun 18, 2007 · Past) | Chairman · Since at least Jun 18, 2014 |
| Annalisa Jenkins Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); Mereo BioPharma Group plc (Director · Since at least Jan 1, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Serina Therapeutics, Inc. (Director · Nov 27, 2018 – Jun 21, 2021 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past) | Director · Apr 20, 2015 – Jun 13, 2019 · Past |
| John Bishop Other companies: Lyra Therapeutics, Inc. (Chief Technology Officer · Feb 27, 2023 – Jan 30, 2024 · Past); Forma Therapeutics Holdings Inc (SVP, Chief Technology Officer · Jun 14, 2021 – Oct 14, 2022 · Past); Veracyte, Inc. (Director · Dec 1, 2014 – Jul 17, 2023 · Past); Cepheid (Chairman of the Board and CEO, Director · Feb 26, 2009 – Nov 4, 2016 · Past); Conceptus Inc (Director · Feb 25, 2009 – Jun 5, 2013 · Past); Momenta Pharmaceuticals Inc (Senior VP, Pharmaceutical Scie · Feb 17, 2006 – May 19, 2016 · Past) | Chief Technical and Quality Officer · Since at least Aug 1, 2025 |
| Richard Rodgers Other companies: Novavax, Inc. (Director · Since at least Oct 29, 2022); Opus Genetics, Inc. (Director · Since at least Dec 2, 2014); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jul 18, 2023 · Past); Tesaro Inc (Executive VP & CFO · Jun 27, 2012 – Mar 6, 2013 · Past); Abraxis BioScience Inc (Senior Vice President and CFO · Jul 9, 2009 – Jul 13, 2009 · Past); Mgi Pharma Inc (Sr. VP and Controller · Jul 15, 2006 – Jan 28, 2008 · Past) | Director · Since at least Jun 18, 2014 |
| Edward R. Conner Other companies: Jade Biosciences, Inc. (Chief Medical Officer · Since at least Apr 23, 2026); Third Harmonic Bio Inc. (Chief Medical Officer · Sep 14, 2022 – Jan 15, 2025 · Past); Enliven Therapeutics, Inc. (Director · Apr 22, 2020 – Jun 2, 2022 · Past); Audentes Therapeutics Inc (SVP, Chief Medical Officer · Jul 15, 2019 – Jan 15, 2020 · Past); Sangamo Therapeutics, Inc. (Sr. VP & Chief Medical Officer · Nov 30, 2016 – Jan 24, 2019 · Past) | Chief Medical Officer · Since at least Aug 1, 2025 |
| Merdad Parsey Other companies: ArriVent BioPharma, Inc. (Director · Since at least Apr 28, 2025); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jun 5, 2024 · Past); Arcus Biosciences, Inc. (Director · Jul 13, 2020 – Jul 13, 2020 · Past); Gilead Sciences, Inc. (Chief Medical Officer · Nov 1, 2019 – Dec 10, 2024 · Past) | Director · Since at least Apr 28, 2025 |
| Susan Rodriguez Other companies: Monopar Therapeutics Inc. (Chief Commercial and Strategy Officer · Since at least Mar 2, 2026); Avadel Pharmaceuticals PLC (Chief Operating Officer · Since at least May 13, 2025); Veradigm Inc. (Director · Since at least Feb 17, 2023); Heron Therapeutics, Inc. (Director · Sep 20, 2021 – Jan 31, 2025 · Past) | Chief Commercial Officer · May 18, 2020 – May 21, 2024 · Past |
| Gordon Ringold Other companies: Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past); Alexza Pharmaceuticals Inc (Director · Mar 8, 2006 – Jun 21, 2016 · Past); Maxygen Inc (Director · Jan 3, 2006 – Jun 6, 2012 · Past) | Director · Jun 18, 2014 – Jun 9, 2020 · Past |
| Muna Bhanji Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Apr 28, 2022); Veracyte, Inc. (Director · Since at least Mar 19, 2021); Cytokinetics, Incorporated (Director · Since at least Feb 17, 2021) | Director · Since at least Mar 11, 2021 |
| Michael Raab Other companies: Tempest Therapeutics, Inc. (Director · Since at least Jun 25, 2021); Amicus Therapeutics Inc (Director · Since at least Jun 9, 2016) | President & CEO, Director · Since at least Jan 19, 2017 |
All 40 people
| Person | Seat |
|---|---|
| Onaiza Cadoret-Manier Other companies: Ventyx Biosciences Inc (Director · Since at least Jan 11, 2023); Ionis Pharmaceuticals, Inc. (EVP,Chf GL Pdt Str & Oper Ofc · Jan 9, 2020 – Feb 2, 2024 · Past) | Director · Since at least Mar 12, 2020 |
| Robert Bazemore Other companies: Akari Therapeutics PLC (Director · Since at least Sep 17, 2024); Nuvation Bio Inc. (Director · Since at least Sep 3, 2024) | Director · Since at least Jun 14, 2024 |
| Elizabeth Grammer Other companies: Sagimet Biosciences Inc. - Series A (Board Member · Since at least Jul 13, 2023) | See Remarks · Since at least Jun 18, 2014 |
| Justin Renz Other companies: Zevra Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 5, 2026) | Chief Financial Officer · Since at least May 20, 2022 |
| Laura Williams Other companies: Enliven Therapeutics, Inc. (Director · Jun 29, 2021 – Jun 2, 2022 · Past) | Chief Patient Officer Emeritus · Since at least Jun 15, 2022 |
| Michael Kelliher Other companies: Capricor Therapeutics, Inc. (Director · Since at least Jan 5, 2026) | Chief Business Officer · Since at least May 20, 2025 |
| Peter G Schultz Other companies: Symyx Technologies Inc (Director · Jan 3, 2006 – Dec 31, 2006 · Past) | Director · Jun 18, 2014 – Jun 11, 2015 · Past |
| Reginald Seeto Other companies: CareDx, Inc. (See Remarks, Director · Nov 26, 2018 – Oct 2, 2023 · Past) | Chief Operating Officer · Oct 22, 2016 – Jan 16, 2018 · Past |
| William C Bertrand Jr Other companies: Adaptimmune Therapeutics PLC (Chief Operating Officer · Since at least Mar 15, 2017) | Director · Since at least Jun 2, 2016 |
| Caitlin Lowie | Ardelyx Investor Relations and Corporate · Since at least Feb 24, 2026 |
| David P Rosenbaum | Chief Development Officer · Jun 18, 2014 – Nov 20, 2024 · Past |
| Eric Duane Foster | Chief Commercial Officer · Since at least May 20, 2025 |
| Felecia Ettenberg | Chief Legal Officer · Since at least Apr 20, 2026 |
| Geoffrey A Block | Director · Jun 15, 2022 – Jun 15, 2023 · Past |
| James Parker Brady | Chief Human Resources Officer · Since at least Jun 18, 2025 |
| Jamie Brady | Chief Human Resources Officer · Since at least Aug 4, 2025 |
| Jeffrey W Jacobs | Chief Scientific Officer · Jun 18, 2014 – Nov 22, 2021 · Past |
| Joseph James Reilly | See Remarks · Since at least Nov 15, 2024 |
| Keith Santorelli | See Remarks · Mar 12, 2020 – Mar 12, 2020 · Past |
| Lindsey Manuel | Associate Director, Corporate Communications · Since at least Nov 3, 2026 |
| Lisa Caperelli | SVP, Investor Relations & Corporate Communications · Since at least Nov 3, 2026 |
| Mike Kelliher | Chief Business Officer · Since at least Aug 4, 2025 |
| Mike Raab | President & Chief Executive Officer · Since at least Aug 25, 2026 |
| Narani Arasaratnam | VP, Corporate Controller · Nov 3, 2014 – Jan 15, 2016 · Past |
| Rajani Dinavahi | Chief Medical Officer · Since at least Nov 3, 2026 |
| Robert Blanks | See Remarks · May 20, 2022 – Nov 20, 2024 · Past |
| Robert Ora Felsch | See Remarks · Mar 10, 2022 – Aug 20, 2024 · Past |
| Sue Hohenleitner | Chief Financial Officer · Since at least Feb 5, 2026 |
| Susan Hohenleitner | Chief Financial Officer · Since at least Nov 4, 2025 |
| William A. Bertrand | Director · Since at least Jun 18, 2026 |
Log in to ask 6ix AI your own questions about Ardelyx, Inc.